Ex­clu­sive: A long­time VC takes on his own rare dis­ease as Sanofi, Boehringer com­mit $80M to launch new plat­form study

Over three decades of in­vest­ing, Luke Evnin has backed and ad­vised dozens of biotechs de­vel­op­ing med­i­cines. Now, the long­time VC is turn­ing his know-how and in­dus­try con­tacts loose on his own rare dis­ease.

The re­sult is a first-of-its-kind Phase IIb tri­al in scle­ro­der­ma, with the study re­cent­ly win­ning the FDA’s OK to be­gin, Evnin ex­clu­sive­ly told End­points News. The study us­es a plat­form de­sign, mean­ing mul­ti­ple drugs will be test­ed against a shared place­bo group. Ad­di­tion­al treat­ments can al­so be added to the tri­al as it pro­gress­es.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER